In 2020, during the COVID-19 pandemic, the nucleic acid extraction and PCR instruments and reagents independently developed and produced by Tianlong have greatly contributed to the prevention and control of the epidemic situations domestically and globally.
In 2019, the 'Fluorescent Digital Gene Amplification Single Molecule Detector' Project led by Tianlong, of the National Key R&D Program of China, was successfully launched in Xi'an, China.
In 2018, Tianlong, with its own sustainable development value, obtained a strategic investment from Shanghai Kehua Bio-Engineering co., Ltd. (stock code: 002022).
In 2016, Tianlong's Intelligent Medical Equipment R&D and Production Project of Independent Medical Laboratory Equipment and Reagents Production Project, i.e. the Medical Health Industrial Park, officially laid the foundation stone.
In 2015, Tianlong invested in Wuxi Ruiqi Gene Biotechnology Co., and started the new era of personalized precision medicine.
In 2014, Tianlong developed the Ebola virus nucleic acid testing kits to help prevent and control the Ebola epidemic in Africa.
In 2013, the project of development and application of automated quantitative detection and high-resolution analysis equipment for nucleic acids, as a National Special Project for the Development of Major Scientific Instruments and Equipment, was officially launched.
In 2009, Suzhou Tianlong Biotechnology Co. was established.
In 2009, the first case of H1N1 was detected in Shaanxi Province by Tianlong, then thousands of cases of influenza A were confirmed in China by us.